Evernorth's Value-Based Models For Containing Drug Spend In Specialty

Recorded on 09/10/24

Evernorth has played a leading role in the development of value-based contracting programs to assist plan sponsors in managing rising pharmaceutical costs. As plan sponsors are faced with the cost impacts of the rising mix of specialty drugs, they are increasingly turning to solutions such as Evernorth's SafeGuardRx, which combines financial arrangements for plans with clinical value-based features for members. Since the launch of SafeGuardRx in 2015, nearly all of Evernorth's plan sponsors have adopted at least one SafeGuardRx program. Evernorth has continued to innovate on solutions that help plan sponsors manage the high costs of innovative pharmaceutical treatments, such as offering the EncircleRx program to help plan sponsors control GLP-1 costs and offering private label biosimilars to provide options to plan sponsors for lower cost specialty drugs. To discuss this topic, we're joined by Harold Carter, Senior Vice President of Pharma Trade Relations at Express Scripts (an Evernorth company).

https://go.td.com/PodcastDisclosure